Relapsed therapy agents and regimens
| Regimen . | ORR (%) . | CR (%) . | PFS . |
|---|---|---|---|
| Ibrutinib48-51 | 68-72 | 19-21 | 13-14.6 mo |
| Acalabrutinib57 | 81 | 40 | Median not reached |
| Lenalidomide68-71 | 28-40 | 5-12 | 4.0-8.8 mo |
| Bortezomib72,73 | 32-41 | 8-21 | 6.5 mo |
| Temsirolimus50,51,74 | 22-40 | 1-2 | 4.8-6.2 mo |
| RI58,59 | 88 | 44 | 43 mo |
| Lenalidomide + rituximab75 | 57 | 36 | 11.1 mo |
| Bortezomib + rituximab76 | 88 | 44 | 12.1 mo |
| Ibrutinib + lenalidomide + rituximab60 | 76 | 56 | Median not reached |
| Venetoclax62 | 75 | 21 | 14 mo |
| Venetoclax + ibrutinib64,65 | 71 | 71 | Median not reached, 12-mo PFS 75%, 18-mo PFS 57% |
| BR77-79 | 71-92 | 38-50 | 17.6-18.1 mo |
| RBAC80 | 80 | 70 | Median not reached, 2 y-PFS 70% |
| Bendamustine + bortezomib + rituximab81 | 71 | 52 | 2-y PFS 47% |
| Cyclophosphamide + doxorubicin + vincristine + prednisone82 | 47 | 21.7 | 8.1 mo |
| Cyclophosphamide + doxorubicin + vincristine + prednisone + bortezomib82 | 82.6 | 34.8 | 16.5 mo |
| Rituximab + gemcitabine + oxaliplatin83 | 83 | 60 | 22 mo |
| Gemcitabine + cisplatin + dexamethasone84 | 44 | 22 | 8.5 mo |
| Regimen . | ORR (%) . | CR (%) . | PFS . |
|---|---|---|---|
| Ibrutinib48-51 | 68-72 | 19-21 | 13-14.6 mo |
| Acalabrutinib57 | 81 | 40 | Median not reached |
| Lenalidomide68-71 | 28-40 | 5-12 | 4.0-8.8 mo |
| Bortezomib72,73 | 32-41 | 8-21 | 6.5 mo |
| Temsirolimus50,51,74 | 22-40 | 1-2 | 4.8-6.2 mo |
| RI58,59 | 88 | 44 | 43 mo |
| Lenalidomide + rituximab75 | 57 | 36 | 11.1 mo |
| Bortezomib + rituximab76 | 88 | 44 | 12.1 mo |
| Ibrutinib + lenalidomide + rituximab60 | 76 | 56 | Median not reached |
| Venetoclax62 | 75 | 21 | 14 mo |
| Venetoclax + ibrutinib64,65 | 71 | 71 | Median not reached, 12-mo PFS 75%, 18-mo PFS 57% |
| BR77-79 | 71-92 | 38-50 | 17.6-18.1 mo |
| RBAC80 | 80 | 70 | Median not reached, 2 y-PFS 70% |
| Bendamustine + bortezomib + rituximab81 | 71 | 52 | 2-y PFS 47% |
| Cyclophosphamide + doxorubicin + vincristine + prednisone82 | 47 | 21.7 | 8.1 mo |
| Cyclophosphamide + doxorubicin + vincristine + prednisone + bortezomib82 | 82.6 | 34.8 | 16.5 mo |
| Rituximab + gemcitabine + oxaliplatin83 | 83 | 60 | 22 mo |
| Gemcitabine + cisplatin + dexamethasone84 | 44 | 22 | 8.5 mo |